News
CAMRF
55.00
NaN%
--
Camurus Expands Share Capital After Employee Stock Option Exercises
TipRanks · 03/31 05:41
Camurus Expands Share Capital After Employee Stock Option Exercises
TipRanks · 02/27 15:34
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Medtronic (MDT) and Camurus AB (OtherCAMRF)
TipRanks · 02/18 12:20
Camurus Strengthens Executive Team With New Corporate Development Chief
TipRanks · 02/17 07:34
Camurus AB Earnings Call: Growth, FX and U.S. Push
TipRanks · 02/15 00:14
Camurus AB (publ) GAAP EPS of SEK1.67, revenue of SEK464M
Seeking Alpha · 02/12 20:08
Camurus Posts Strong 2025 Earnings, Expands Long-Acting Endocrine Portfolio
TipRanks · 02/12 06:35
Camurus announces FDA acceptance of NDA resubmission for Oclaiz
TipRanks · 01/09 14:40
Camurus’ acromegaly drug Oclaiz gains FDA review date after resubmitted US filing
TipRanks · 01/09 14:32
Camurus: Why It Has Become A Meaningful Position In Our Portfolio
Seeking Alpha · 01/09 11:57
Camurus Increases Share Capital After Employee Stock Option Exercise
TipRanks · 12/30/2025 06:32
Camurus Increases Shares and Votes Following Employee Stock Option Exercise
TipRanks · 11/28/2025 06:32
Camurus Announces Nomination Committee for AGM 2026
TipRanks · 11/13/2025 06:34
Camurus AB Earnings Call: Growth Amid Challenges
TipRanks · 11/11/2025 00:08
Camurus Reports Positive Phase 1b Results for Monthly Semaglutide Depot
TipRanks · 11/10/2025 07:45
Camurus AB Reports Strong Q3 Growth Amid Revised Outlook
TipRanks · 11/07/2025 05:11
Camurus AB (publ) reports Q3 results
Seeking Alpha · 11/06/2025 17:47
Camurus AB Reports Strong Q3 2025 Financial Performance and Strategic Milestones
TipRanks · 11/06/2025 06:35
Camurus Increases Shares and Votes Following Employee Stock Option Exercise
TipRanks · 09/30/2025 05:33
Weekly Report: what happened at CAMRF last week (0908-0912)?
Weekly Report · 09/15/2025 09:39
More
Webull provides a variety of real-time CAMRF stock news. You can receive the latest news about Camurus Sweden through multiple platforms. This information may help you make smarter investment decisions.
About CAMRF
Camurus AB is a Sweden-based research and development based pharmaceutical and biotechnology company with a focus on the development and marketing of specialty medicines, providing patients suffering from severe and chronic disease, such as opioid dependence, pain, cancer, and endocrine diseases. The Company has a diversified research portfolio, which includes products in clinical trials. The Company’s products are based on FluidCrystal formulation technology. FluidCrystal is Company's patent-protected technology platform. Camurus AB is the parent company of the Group, which comprises of legal entities, namely: Camurus Inc, Cubosome Inc, Development AB, Camurus GmbH, Camurus Ltd, Camurus Oy, Camurus AS, Camurus SAS, Camurus Pty Ltd, Camurus S.L, Camurus ApS, Camurus BV and Camurus Austria GmbH.